Correspondence to Dr Chanu Rhee, Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA; crhee{at}bwh.harvard.edu Sepsis, the syndrome ...

Objective To perform a network meta-analysis of randomised controlled trials of different surfactant treatment strategies for respiratory distress syndrome (RDS) to assess if a certain fraction of ...

Objectives COVID-19 causes lung parenchymal and endothelial damage that lead to hypoxic acute respiratory failure (hARF). The influence of hARF severity on patients’ outcomes is still poorly ...

The SOFA-2 score included new definitions, new variables, and revised thresholds to categorize the severity of organ dysfunction in critical illness. The updates reflected changes in practice, ...

ABSTRACT: Background: There is a paucity of data on the efficacy of ventilatory strategies in COVID-19-related ARDS. The aim of this study was to describe the effect of positive end-expiratory ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

The following is a summary of “Prognostic value of PaO2/FiO2 ratio in predicting clinical outcomes in COVID-19 patients,” published in the June 2024 issue of Critical Care by Canto-Costal et al.

The models use maximal deflection of esophageal pressure to quantify HFOT-related breathing effort (ΔPes) and the risk for strong breathing effort (ΔPes >10 cmH2O). Two models have been developed to ...

Introduction The use of fibrinolytic therapy has been proposed in severe acute respiratory distress syndrome (ARDS). During the COVID-19 pandemic, anticoagulation has received special attention due to ...

Clinical question: Do the anti-inflammatory and immunomodulatory effects of glucocorticoids decrease mortality among patients with severe community-acquired pneumonia (CAP)? Background: CAP remains a ...